EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Äquivalenzstudie

Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study)

Masanori Tokunaga iD, Nozomu Machida, Junki Mizusawa, Seiji Ito, Hiroshi Yabusaki, Motohiro Hirao, Masaya Watanabe, Hiroshi Imamura, Takahiro Kinoshita, Takushi Yasuda, Jun Hihara, Haruhiko Fukuda und 3 weitere

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01467-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Gastric Cancer, 2024. Verfasst von Masanori Tokunaga und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, Japan. tokunaga.srg1@tmd.ac.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: AMED, National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophageal NeoplasmsHumansTrastuzumabLymphatic MetastasisJapanErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsEsophagogastric JunctionMedical OncologyNeoadjuvant Therapy

Stichwörter der Autor:innen

Gastric cancerHER2Neoadjuvant chemotherapyTrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, Japan. tokunaga.srg1@tmd.ac.jp.
  • Department of Gastroenterology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.

ORCID-Profile: Masanori Tokunaga

Förderung

  • AMED
  • National Cancer Center Research and Development Fund

Zitieren

APA

Tokunaga, M., Machida, N., Mizusawa, J., Ito, S., Yabusaki, H., Hirao, M., Watanabe, M., Imamura, H., Kinoshita, T., Yasuda, T., Hihara, J., Fukuda, H., Yoshikawa, T., Boku, N., & Terashima, M. (2024). Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. https://doi.org/10.1007/s10120-024-01467-9

Vancouver

Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024. doi:10.1007/s10120-024-01467-9

BibTeX
@article{Tokunaga2024,
  author = {Tokunaga, Masanori and Machida, Nozomu and Mizusawa, Junki and Ito, Seiji and Yabusaki, Hiroshi and Hirao, Motohiro and Watanabe, Masaya and Imamura, Hiroshi and Kinoshita, Takahiro and Yasuda, Takushi and Hihara, Jun and Fukuda, Haruhiko and Yoshikawa, Takaki and Boku, Narikazu and Terashima, Masanori},
  title = {Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study)},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01467-9}
}
Kostenlos starten →